Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$13.40
▲ $0.05 (+0.4%)
Market data updated: 09/19 06:23 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$171.99M
Day Range
$13.30 - $13.49
52-Week Range
$12.52 - $20.03
Beta
—
Next Earnings
18.11.2026
Support
$12.52
Resistance
$14.95
MDWD is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-20.1% (1Y)
Strengths: 9/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 30.7%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$35.46 vs. price $13.40 (-364.6%)
Fair Value
Signal tension
Growth scores strong (60/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
45
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
60
Quality
55
Value
38
Momentum
35
Risk
46
Sentiment
74
Fundamental
31
Institutional
68
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of MediWound Ltd. highlights its progress in advancing its medical wound care products, particularly the **EscharEx** program, which reached Phase III enrollment for treating chronic wounds. The company also reported **record sales for NexoBrid**, its burn treatment, while expanding its market potential to $1.05 billion annually. Analysts, including Oppenheimer’s Jeff Jones, maintained an **Outperform rating** despite a slight price target adjustment. The company’s manufacturing facility nears regulatory completion, and it reaffirmed its 2026 financial guidance amid continued investment in R&D.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about MediWound Ltd.. News trend score: 74. Reason: 7 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
16
🎯 Conviction (vs. Emotion)
52
Psychology
18
Fundamentals
31
Technical
35
Valuation
38
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-6%
Market Narrative
61
Fundamental Reality
52
Narrative Gap
+9
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
MDWD’s market behavior suggests a **FOMO-driven momentum trade**—supported by positive momentum, elevated volume, and positive sentiment—though euphoria and overconfidence are muted by underperformance relative to its 200-day average. The narrative gap (5 points) hints at a disconnect between market enthusiasm and fundamentals, with traders potentially chasing price gains over valuation. The absence of panic or herding implies a disciplined, momentum-focused approach rather than emotional extremes. The key question: *Will traders sustain momentum chasing despite the stock’s lagging valuation?*
Updated: 09/09/2026, 06:45 AM
What could change this?
👥 What the crowd believes
"reaffirms 2026 guidance with record NexoBrid quarterly sales, expands market opportunity to $1.05 billion in peak annual sales"
"EscharEx advances Phase III enrollment while manufacturing facility nears regulatory completion"
"continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid"
"Oppenheimer analyst lowers price target from $32 to $30 while maintaining Outperform rating"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 100/100
🔴 Weakest match
Philip Fisher — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for MDWD reflects a clash between growth-focused and value-driven methodologies. Peter Lynch’s near-perfect score highlights his enthusiasm for stocks where earnings growth hasn’t yet been fully priced in, while Benjamin Graham’s lower scores—especially for the Enterprising Investor—signal skepticism about the stock’s valuation margins. Meanwhile, Fisher’s zero score underscores his strict criteria for quality and growth, leaving him unimpressed by MDWD’s profile. On the other hand, liquidity-focused analysts like Walter Bagehot and cycle-aware investors like Howard Marks (Market Cycle) see more resilience or moderate risk, contrasting sharply with the caution of Livermore and Nelson, who spot no clear trend or overbought conditions. The efficient-market camp and Morgan Housel further dampen enthusiasm, questioning whether MDWD’s volatility or lack of edge justifies active selection over passive strategies.
Peter Lynch
One Up on Wall Street (1989)
🟢 100
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 87
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 80
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 66
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 64
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 58
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 57
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 57
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 53
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 49
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 41
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 35
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 32
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 6 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
19.2%
Operating Margin
-149.0%
Net Margin
-140.8%
EBITDA Margin
—
ROE
-54.7%
ROA
-27.7%
ROIC
—
EPS
-$2.10
Cash
$4.80M
Total Debt
—
Current Ratio
2.33
Debt/Equity
0.20
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$13.40
Estimated Fair Value (DCF)
-$35.46
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-364.6%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-23.79M | $-21.82M |
| 2 | 8.1% | $-25.72M | $-21.65M |
| 3 | 6.3% | $-27.33M | $-21.10M |
| 4 | 4.4% | $-28.52M | $-20.21M |
| 5 | 2.5% | $-29.24M | $-19.00M |
Base FCF (last actual year)
$-21.63M
Terminal Value
$-461.06M
Present Value of Terminal Value
$-299.66M
Enterprise Value
$-403.44M
Net Debt
$0
Equity Value
$-403.44M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.40
Tangible Book Value per Share (Tangible NAV)
$3.40
Sentiment based on basic keywords (not AI) — 7 positive, 10 neutral, 3 negative out of the last 20 articles.
GlobeNewswire · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 20.8.2026
Motley Fool · 20.8.2026
Benzinga · 14.8.2026
MT Newswires · 14.8.2026
Yahoo · 14.8.2026
Moby · 14.8.2026
Yahoo · 13.8.2026
GuruFocus.com · 13.8.2026
Yahoo · 13.8.2026
MarketBeat · 13.8.2026
SeekingAlpha · 13.8.2026
Yahoo · 13.8.2026
Zacks · 13.8.2026
Associated Press · 13.8.2026
Yahoo · 13.8.2026
GlobeNewswire · 13.8.2026
MediWound Ltd. (MDWD) currently has a StockIQ AI score of 45/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
MDWD currently scores 45/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, MDWD's estimated fair value is -$35.46, which is 364.6% below the current price of $13.40. This is one valuation model among several signals in the fair-value category, not a price target.
MDWD's technical score is 35/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 30.7%; Net income growth: 21.0%; Debt/equity: 0.20.
Based on the real signals StockIQ computed: Estimated fair value: -$35.46 vs. price $13.40 (-364.6%); Operating margin: -149.0% (negative); Net margin: -140.8% (negative).
StockIQ has no recorded dividend payment history for MDWD.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 13 purchases and 6 sales out of the last 23 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Rubinstein Samuel | Open Market Sale | 1.9.2026 | 525 | -525 | $12.72 |
| Rubinstein Samuel | Open Market Purchase | 1.9.2026 | 525 | +525 | $12.62 |
| Hess Shmuel | Open Market Sale | 27.8.2026 | 0 | -1,979 | $12.72 |
| Hess Shmuel | Exercise of Derivative Securities | 27.8.2026 | 16,000 | -11,000 | — |
| Hess Shmuel | Exercise of Derivative Securities | 27.8.2026 | 11,000 | -11,000 | — |
| Hess Shmuel | Open Market Sale | 27.8.2026 | 1,979 | -1,979 | $13.13 |
| Hess Shmuel | Open Market Sale | 27.8.2026 | 1,979 | -1,979 | $12.72 |
| Hess Shmuel | Open Market Sale | 26.8.2026 | 0 | -1,865 | $13.00 |
| Hess Shmuel | Exercise of Derivative Securities | 26.8.2026 | 27,000 | -5,000 | — |
| Hess Shmuel | Open Market Sale | 26.8.2026 | 1,865 | -1,865 | $13.00 |
| Hess Shmuel | Exercise of Derivative Securities | 26.8.2026 | 5,000 | -5,000 | — |
| SHAMIR NACHUM | Open Market Purchase | 3.6.2026 | 5,825 | +5,825 | $14.00 |
| SHAMIR NACHUM | Open Market Purchase | 3.6.2026 | 175 | +175 | $13.98 |
| SHAMIR NACHUM | Open Market Purchase | 3.6.2026 | 49,990 | +175 | $13.98 |
| SHAMIR NACHUM | Open Market Purchase | 3.6.2026 | 55,815 | +5,825 | $14.00 |
| Fox David Morton | Open Market Purchase | 1.6.2026 | 10 | +10 | $14.23 |
| Fox David Morton | Open Market Purchase | 1.6.2026 | 1,730 | +1,730 | $14.23 |
| Fox David Morton | Open Market Purchase | 1.6.2026 | 1,797 | +1,797 | $14.00 |
| Fox David Morton | Open Market Purchase | 1.6.2026 | 20,476 | +1,730 | $14.23 |
| Fox David Morton | Open Market Purchase | 1.6.2026 | 20,486 | +10 | $14.23 |
| Fox David Morton | Open Market Purchase | 1.6.2026 | 22,283 | +1,797 | $14.00 |
| Rubinstein Samuel | Open Market Purchase | 29.5.2026 | 150 | +150 | $14.33 |
| Rubinstein Samuel | Open Market Purchase | 29.5.2026 | 2,993 | +150 | $14.33 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,627,553 shares short as of 2026-08-31 · vs. 1,612,427 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
69.8% of trading volume this week was short selling, vs. 70.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology